Last updated on April 18, 2014 at 16:49 EDT

TrialReach Secures $1.2m in Funding to Expand it’s Discovery Platform for Clinical Trials and Patient Recruitment Services

October 27, 2011

LONDON, October 27, 2011 /PRNewswire/ –

TrialReach ( http://www.trialreach.com) is a groundbreaking website
that helps patients with any medical condition to explore, understand and
access the latest clinical trials [http://www.trialreach.com/howitworks ],
anywhere in the world. The Internet and social media have enabled patients
to become much more deeply involved in managing their own diseases and there
has been an explosion of online information. However, the information about
new treatments and clinical trials has remained, until now, obscure and
inaccessible for the majority of those patients looking online for help. At
the same time, every day, thousands of new patients are needed in projects
designed to prove the effectiveness of new medical treatments and devices.
TrialReach’s unique website combines a specialised search engine, exclusive
patient-friendly information and fast communication channels between
patients and physicians to make clinical trials easy to find, easy to
understand, and easy to access.

“Our strategy is based on empowering patients through content, tools and
context, a formula that has revolutionized other sectors but was never tried
before in clinical trials. The results so far have greatly exceeded our
initial expectations. Thousands of patients have signed up for studies
through our website, and hundreds of them have been put in contact with the
investigators after passing a strict triple-filter process,” said Pablo
Graiver [http://www.trialreach.com/about/team ], co-founder and CEO of

UK technology investor Amadeus Capital Partners Ltd. recently led an
investment of $1.2 million in the company to further develop the TrialReach
platform with the addition of new tools and content for patients and
clinical trial sponsors [http://www.trialreach.com/sponsors ], and to enable
the expansion their services to other languages and territories around the
world. Alex van Someren, General Partner in the Amadeus & Angels Seed Fund,
said: “I was impressed from the outset by the importance of what TrialReach
does in quickly connecting patients with treatments which could help them.
Even better, the company was founded by a team with real experience in
building successful technology businesses. I’m genuinely excited about the
potential for TrialReach to improve people’s lives, save trial sponsors time
& money, and build a global business for our investors.”

TrialReach works closely with investigators and clinical trial sponsors,
including global pharmaceutical companies, biotech companies and clinical
recruitment organisations (CROs), to create fresh online multimedia
descriptions of the studies, as well as their accompanying user-friendly
pre-screening questionnaires. The solution includes a feature that gives
patients the option to forward their own questions to healthcare
professionals, usually the actual investigators of each study. Jessica Mann
MD PhD, co-founder and Chief Medical Officer of TrialReach, noted: “The
benefits of TrialReach’s tools, both to patients and to the industry, can be
quite literally life-changing. I have experienced the patient recruitment
problem first-hand for many years and for the first time I believe that
through TrialReach there is a real, lasting solution that is friendly,
efficient and extremely cost-effective.”

TrialReach is presenting at the Health 2.0 Europe Conference in Berlin,
27-28th October 2011, where the company will be unveiling their new website
to the public.

About TrialReach Ltd.

Headquartered in London, England, TrialReach is a global search and
referral engine for clinical trials, dedicated to making clinical trials
easy to find out about, understand, and get access to. TrialReach uses the
latest online technologies and marketing tools to bridge the gap between
patients wanting to take part in clinical trials and sponsors and
investigators seeking to recruit participants. For more information about
the company, visit http://www.trialreach.com

SOURCE TrialReach

Source: PR Newswire